Samsung Biologics Labor Unrest Fears Ease: Profit Resilience Samsung Biologics is rated Buy: labor unrest threatens production, but latest results show operating profit and net income growth despite revenue collapse, suggesting the stock’s risk discount may be excessive. 2026년 05월 05일 English
SK Hynix Revenue Jumps 66%: AI Memory Outlook Strong SK Hynix is rated Buy: AI memory surge drives major YoY revenue and profit growth, with exceptional margins, SOCAMM2 ramp and Cheongju packaging boosting supply execution despite Samsung competition risks. 2026년 04월 22일 English
